Alnylam Pharmaceuticals, Inc. (ALNY) — Insider Activity & Signal

Healthcare · Biotechnology · Market cap $35.6B · $266.99 · 52-week range $264.21–$495.55

Recent insider buying

Open-market purchases reported to the SEC (last six months). Option grants and tax-withholding sales are excluded.

No qualifying open-market insider purchases on file in the last six months.

Financial health

Altman Z-Score 5.57 · Piotroski F-Score 7/9 · Cash $2.9B · Debt $1.3B

ClearOcean signal read

ClearOcean's model currently scores ALNY as a watchlist-level signal (5/10), based on the insider, fundamental and risk data above. This is a factual model output, not advice.

Sources & further reading

Primary filings: SEC EDGAR — ALNY Form 4
How ClearOcean reads insider activity

Last updated July 23, 2026.

ClearOcean is a software research tool, not an investment adviser or broker-dealer. This page aggregates public data (incl. SEC filings) for informational purposes only — it is not investment advice, nor a recommendation, offer or solicitation to buy or sell any security. Past activity does not predict future results. You are solely responsible for your decisions; investing can lose value, up to total loss of capital.